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INTRODUCTION 
 
                          Thyroid hormone has a fundamental role in the 
cardiovascular homeostasis, both in physiological and pathological 
conditions. Changes in peripheral thyroid hormone concentration 
and metabolism can occur in euthyroid patients suffering from heart 
failure. In heart failure the main alteration of the thyroid function is 
referred to as low-T3 (triiodothyronine) syndrome or euthyroid sick 
syndrome, characterized by the reduction in serum total T3 and 
free T3 with normal levels of thyroxine and thyrotropin. This low-T3 
syndrome has commonly been interpreted as an adaptive 
compensatory and beneficial response that decreases energy 
consumption in diseased states. 
         Heart failure is a complex clinical syndrome that 
can result from any structural or functional cardiac disorders that 
impairs the ability of ventricles to fill with or eject blood1. Coronary 
artery disease accounts for a substantial portion of patients with 
chronic heart failure. 
                           Survival is markedly shortened in patients with 
heart failure. The over all 5-year mortality for all patients with heart 
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failure is approximately 50 percent and the 1-year mortality in 
patients with end stage heart failure may be as high as 75 percent2. 
                           The role of various biological and neurohormonal 
factors in risk stratification of chronic heart failure has been studied 
in various clinical trials. Noradrenaline,angiotensinII, Atrial 
natriuretic peptide (ANP) and Brain natriuretic  peptide (BNP) are 
used as important prognostic markers in patients with heart 
failure3.Recent studies have explored the use of triiodothyronine 
levels to predict mortality in heart failure patients. 
                          Studies suggest that low T3 (triiodothyronine) 
levels correlate with increased mortality in chronic heart failure 
patients and benefits can be gained from thyroid hormone 
supplementation4,5. 
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AIM OF THE STUDY 
 
 
 
• To estimate the prevalence of low-T3 
(triiodothyronine) syndrome in chronic heart failure 
 
• To assess the role of Total T3 as an adjunct to 
clinical and functional parameters when estimating 
mortality in patients with chronic heart failure.           
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REVIEW OF LITERATURE 
 
                             In the past decade, progress in the understanding of 
heart failure has proceeded at an unprecedented rate. Scientific discovery 
and development in fields as disparate as epidemiology and molecular 
biology, has provided profound insights into the mechanism and treatment 
methods of heart failure. 
 
DEFINITION OF HEART FAILURE 
 
                                           In 1933,Thomas Lewis defined heart failure as 
"A condition in which the heart fails to discharge its contents adequately". 
 
                                           The Task Force of the European Society of 
Cardiology6 in 1995 stated diagnosis of heart failure consists of 
"Symptoms of heart failure, objective evidence of cardiac dysfunction and 
response to treatment directed towards heart failure". 
  
                                The most accepted and practical definition of 
heart failure appeared in 2001 ACC/AHA guidelines7 for the evaluation and 
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management of chronic heart failure in adults, which states “Heart failure is 
a complex clinical syndrome that can result from any structural or 
functional cardiac disorders that impairs the ability of ventricles to fill with 
or eject blood”. 
                                          
                        Heart failure is a clinical syndrome that is characterized by 
specific symptoms (dyspnea and fatigue) in the medical history and signs 
(edema, rales) on the physical examination. There is no single test for 
heart failure because it is largely a clinical diagnosis that is based on 
careful history and physical examination. Because not all patients have 
volume overload at the time of initial or subsequent evaluation the term 
heart failure is preferred over the older term  “congestive heart failure”. 
 
EPIDEMIOLOGY OF HEART FAILURE 
 
                         The Framingham heart study8 has been the most important 
longitudinal source of data on the epidemiology of heart failure. The 
prevalence of HF 7.4/1000 in males, 7.7/1000 in females. The annual 
incidence of HF per 1000 population is 2.3 in males and 1.4 in females. 
 
 6
                          The recent Hillingdon study examined the incidence of 
heart failure, defined on the basis of clinical and radiographic findings, with 
echocardiography, in a population in west London. The overall annual 
incidence was 0.08%, rising from 0.02% at age 45-55 years to 1.2% at age 
86 years or over. 
 
ACUTE vs. CHRONIC HEART FAILURE 
 
                          Acute heart failure is defined as the rapid onset of 
symptoms and signs secondary to abnormal cardiac function. It may occur 
with or without previous cardiac disease. The cardiac dysfunction can be 
related to systolic or diastolic dysfunction, to abnormalities in cardiac 
rhythm, or to preload and afterload mismatch. It is often life threatening 
and requires urgent treatment. 
 
                          Chronic heart failure develops and progresses slowly. LV 
dysfunction begins with injury or stress to the myocardium and is a 
progressive process. This progression leads to change in geometry and 
structure of LV such that the chamber dilates or hypertrophies, a process 
termed cardiac remodelling.cardiac remodelling contributes substantially to 
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progressive worsening of heart failure .The course of development of heart 
failure is classified into 4 stages. 
 
STAGES OF CHRONIC HEART FAILURE9 
STAGE A. AT HIGH RISK FOR HEART FAILURE – conditions strongly   
                  associated with development of heart failure. No identifiable                  
                  structural or functional abnormalities of pericardium,    
                  myocardium or cardiac valves. No history of signs and      
                  symptoms of heart failure  
                                                                                                                  
STAGE B. STRUCTURAL HEART DISEASE BUT WITH OUT SIGNS AND       
                  SYMPTOMS OF HEART FAILURE 
 
STAGE C. CURRENT OR PRIOR SYMPTOMS OF HEART FAILURE  
                  ASSOCIATED WITH UNDERLYING STRUCTURAL HEART    
                  DISEASE 
 
STAGE D. ADVANCED STRUCTURAL HEART DISEASE AND MARKED  
                 SYMPTOMS OF HF AT REST DESPITE MAXIMAL MEDICAL  
                 THERAPY. REQUIRE SPECIAL INTERVENTIONS 
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ETIOLOGY OF CHRONIC HEART FAILURE 
 
                           Impairment of left ventricle function accounts for majority of 
symptoms in heart failure. Coronary artery disease, hypertension and dilated 
cardiomyopathy accounts for substantial proportion of heart failure.valvular 
heart disease and anemia are common causes of HF in Indian population. 
Arrhythmias, pericardial diseases, shunts and thyrotoxicosis are other less 
common causes. 
                           World wide CAD accounts for two thirds to three fourths of 
the causes of HF.  In NHANES I epidemiological follow-up study10 coronary 
artery disease was the major cause of HF in 61.1% of patients. The 
Glasgow group of the MONICA study and the ECHOES Group have found 
that coronary artery disease is the most powerful risk factor for impaired left 
ventricular function AND HF. 
 
CORONARY ARTERY DISEASE AND CHRONIC HEART FAILURE 
 
                          Several factors contributing to LV dysfunction and hence 
symptoms of chronic heart failure in coronary artery disease. Almost 50% 
of patients surviving myocardial infarction develop heart failure. 
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                          Loss of functioning myocytes and myocardial fibrosis 
following acute myocardial infarction leads to LV remodeling and chamber 
dilatation. Significant atherosclerotic disease in coronary arteries other than 
the infarct-related artery and neurohormonal activation lead to progressive 
dysfunction of the remaining viable myocardium. In addition recurrent 
myocardial infarction may produce future deterioration of LV function. 
 
                           Exertion superimposes ischemia on the ventricle with 
irreversibly damaged myocardium, which may cause prolonged systolic 
dysfunction that persists even after the ischemic insult itself has resolved. 
This phenomenon is termed exercise-induced "stunning,"11  and has been 
shown to be associated with progression of LV dysfunction. 
 
                          Myocardial  "hibernation."12  refers to adaptive response to 
sustained reduction in myocardial blood flow, in which the level of tissue 
perfusion is sufficient to maintain cellular viability but insufficient for normal 
contractile function, further compromising LV function. 
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                           The baroreceptor mediated activation of sympathetic 
nervous system13  that occurs with ventricular dysfunction leads to 
vasoconstriction, tachycardia, increased contractility, increased preload 
and after load. Increased local and systemic levels of norepinephrine 
induce apoptosis and is directly toxic to the myocytes. 
 
                           The activity of renin angiotensin aldosterone system is 
increased in patients with heart failure. Raised angiotensin II and 
aldosterone levels have a mitogenic effect on cardiac myocytes with 
resultant LV remodeling.Chronic neurohormonal activation affects myocyte 
growth, interstitial connective tissue, myocardial energy utilization, and 
receptor regulation further detoriating LV function. 
 
SYSTOLIC AND DIASTOLIC HEART FAILURE 
 
                           In chronic ischemic heart disease systolic heart failure is 
caused by both the chronic loss of contracting myocardium secondary to 
prior myocardial infarction and the acute loss of myocardial contractility 
induced by transient ischemia. Diastolic heart failure is due to ventricle’s 
reduced compliance caused by replacement of normal, distensible 
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myocardium with nondistensible fibrous scar tissue and by acute reduction 
of diastolic distensiblity during ischemia. 
 
                 The principle manifestation of systolic heart failure is due to 
inadequate cardiac output or salt and water retention or both. Diastolic 
heart failure leads to elevated ventricular filling pressures leading to 
pulmonary and systemic venous congestion. 
 
ECHOCARDIOGRAPHY IN CHRONIC HEART FAILURE 
 
                  The ACC/AHA guidelines recommend that, two-dimensional 
echocardiography should be performed during initial evaluation of patients 
presenting with HF to assess LV ejection fraction, LV size, wall thickness 
and valve function. It improves diagnostic accuracy and guides treatment 
of heart failure14. Recent studies support the use of echocardiography as a 
screening tool for heart failure in high risk patients15. 
 
                   LV systolic function can be assessed by M-mode, 2-D and 
Doppler techniques.M-mode gives excellent resolution and measurement 
of  LV dimensions and wall thickness. 
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                                 2-D technique is used to measure LV volumes and 
ejection fraction. The LV is divided into 16 segments and an assessment of 
regional wall motion is made. A segments systolic motion16 is classified as 
• Normal 
• Hypokinetic (reduced movement) 
• Akinetic (absent movement) 
• Dyskinetic (movement in wrong direction) 
• Aneurysmal (out pouching of all layers of the wall) 
 
                                The echocardiographic evidence of regional wall 
motion abnormalities has been used in clinical diagnosis of coronary artery 
disease17. Presence of frank scars, aneurysm and any truly normally 
functioning segments point to the diagnosis of ischemic LV dilatation and 
dysfunction. 
 
                                 Doppler echo is useful in estimating the severity of 
mitral regurgitation and to measure pulmonary artery pressure using the 
gradient of tricuspid regurgitation. 
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                                   Coronary artery disease is the most common 
condition in which systolic and diastolic dysfunction coexists. Functional 
capacity appears related not only to systolic function, but also to diastolic 
function18. M-mode techniques have been used to record the rate of 
relaxation of ventricular cavity. Doppler echo19 currently is the primary 
technique used for evaluating ventricular diastolic function. With normal 
pressures the early diastolic mitral velocity  (E) exceeds the following atrial 
systole or late mitral (A) velocity (E/A ratio greater than 1). Decreased LV 
relaxation due to diastolic dysfunction decrease in E velocity and increase 
in A velocity. The E/A ratio is less than 1 and the isovolumic relaxation time 
(IVRT) is prolonged. 
 
                                  Ejection Fraction (EF) measured by 
echocardiography is the most important measure of LV systolic function. 
Though MUGA scan can measure Ejection Fraction more accurately, the 
ability of echocardiography to measure valvular and wall motion 
abnormalities makes it a class I (definite evidence that it is useful and 
beneficial) investigation in initial evaluation of HF. 
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                                     Studies involving chronic heart failure use reduced 
ejection fraction as definite evidence of LV dysfunction. EF of less than 
45% is used as a cut off in most of these studies.  
 
RISK STRATIFICATION IN CHRONIC HEART FAILURE6  
 
                 Risk stratification is prudent to determine the mortality and 
morbidity profile of patients with HF. It helps to identify patients who is at 
low risk and therefore can be managed medically. Invasive procedures 
should be reserved for patients at high risk of mortality. 
                 The following parameters are strongly associated with increased 
mortality in chronic heart failure and are recommended in risk stratification. 
 
• Advanced age 
• Low serum sodium 
• VO2 max  (mL/kg per min <10–14) 
• Low LV ejection fraction20 
• Resuscitated sudden death 
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• NYHA functional Class III–IV 
• Persistent low BP 
• High serum BNP30,21 
• Increased left ventricular volumes 
• High serum creatinine  
• High serum bilirubin 
 
                               Studies show that Low body-mass index, Broad QRS22, 
T-wave alternans23, Low heart rate variability, Low 6 min walking ability, 
High left ventricular filling pressure, Restrictive mitral filling pattern24, 
Impaired right ventricular function, High serum uric acid 25,high plasma 
Interleukin –626, high plasma Oxidised LDL27 Low cardiac index, High 
resting heart rate and High serum norepinephrine28 portend bad prognosis 
in these patients.  Recently Homocysteine29Levels are found to be 
associated with Increased risk of HF. 
 
                                    The inherent limitations associated with these     
factors necessitate the use of more than one factor in prognostication of 
chronic HF. Predictability and cost efficacy concerns have inculcated 
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further studies in this area. Recently the prognostic role of T3 in this 
population is being explored by various studies. 
 
THYROID HORMONE & HEART 
 
                  Thyroid hormone increases cardiac contractility directly and 
indirectly by increasing peripheral oxygen consumption and substrate 
requirements. 
 
                   Triiodothyronine decreases systemic vascular resistance by 
dilating the resistance arterioles of the peripheral circulation. The 
vasodilation is due to a direct effect of triiodothyronine on vascular smooth-
muscle cells that promotes relaxation. Thyroid hormone increases blood 
volume. Thyroid hormone also stimulates erythropoietin secretion. The 
combined effect of these two actions is an increase in blood volume and 
preload, which further increases cardiac output31 . 
 
                    Predictable changes in myocardial contractility and 
hemodynamics occur across the entire spectrum of thyroid disease. 
Hyperthyroidism is characterized by increased cardiac contractility, cardiac 
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output and high output failure. Hyperthyroidism induced sustained sinus 
tachycardia or atrial fibrillation further reduces ventricular contractility32. 
Experimental studies have shown that there is increased expression of 
beta 1 adrenergic receptors and enhanced cathecholamine sensitivity in 
hyperthyroidism. Hypothyroidism is associated with diastolic hypertension 
and decreased contractility of myocardium. Hypothyroidism can lead to 
severe, progressive systolic dysfunction and increased chamber 
diameter/wall thickness ratio despite a reduction in cardiac mass33. There is 
often pericardial effusion but rarely produces any symptoms.  
 
                    Subclinical hypothyroidism is diagnosed when serum TSH is 
high and both T4 and T 3 are normal. Studies indicate that Subclinical 
hypothyroidism is associated with impaired vasodilatation , which can be 
corrected with thyroxine therapy34. Subclinical hyperthyroidism is 
diagnosed when serum TSH is low and both T4 and T 3 are normal. There 
is increased prevalence of atrial fibrillation and increased cardiovascular 
mortality35 in subclinical hyperthyroidism. In contrast Low T3 syndrome is 
diagnosed when TSH is normal and T3 levels are low. 
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MECHANISM OF ACTION  
                                             
                                  Triiodothyronine is the active form that enters the 
myocyte. In the myocyte, triiodothyronine enters the nucleus and binds to 
nuclear receptors that then bind to thyroid hormone response elements in 
target genes and regulates transcription of these genes including those for 
Ca2+-ATPase36 and phospholamban37 in the sarcoplasmic reticulum, 
myosin, -adrenergic receptors, adenylyl cyclase, guanine-nucleotide–
binding proteins, Na+/Ca2+ exchanger, Na+/K+–ATPase, and voltage-gated 
potassium channelsu. In the absence of triiodothyronine, the receptors 
repress genes that are positively regulated by thyroid hormone. Studies 
have shown that thyroid hormone can regulate the genetic expression of 
its own nuclear receptors within the cardiac myocytes. 
                                  Thyroxine (T4), which is derived solely from the 
thyroid gland, normally constitutes the greatest volume of serum thyroid 
hormone. Triiodothyronine (T3), which is three to five times more potent 
than T4, is produced both by the thyroid gland and by peripheral 
conversion of T4 to T3. Conversion involves peripheral monodeiodination 
of thyroxine in tissues such as heart, liver, kidney, and gut mucosa by the 
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type I deiodinase. T3 induces expression of type I deiodinase38. The type II 
deiodinase provides intracellular triiodothyronine in specific sites such as 
central nervous system and pituitary39.In addition, T4 is converted to 
reverse T3 (rT3), a metabolically inactive thyroid hormone, by 5-
deiodinase.  
LOW T3 SYNDROME 
 
                                The terms sick euthyroid syndrome, nonthyroidal 
illness syndrome, euthyroid sick syndrome (ESS) and low T3 syndrome 
are used interchangeably.   
                           The term low T3 syndrome or sick euthyroid syndrome 
is defined as “The transient changes in serum thyroid hormone levels 
as well as the alterations in thyroid hormone metabolism induced by 
systemic illnesses in patients without concurrent hypothalamic, pituitary 
or thyroid diseases, and does not imply thyroid hormone status”.                  
                        
 The syndrome has been described in various illnesses like  
• Chronic kidney disease40 
• Tuberculosis, respiratory failure41 
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• Heart failure 
• Acute myocardial infarction42 
• Cardiopulmonary bypass             
• Starvation 
• Sepsis 
• Burns 
• Trauma 
• Surgery 
• Malignancy 
• Bone marrow transplantation43 
 
                       The frequency of varies from 20 to 50%. Frequency 
depends on the severity of illness than on the type of illness. The highest 
incidence occurs in the most severely ill group. 
                        The syndrome affects both sexes equally and affects 
people at all ages. Because of the increased incidence of chronic illness at 
advanced ages the syndrome is more common in elderly age groups. 
                        There is no specific imaging study to diagnose low T3 
syndrome. Thyroid sonogram, thyroid uptake scan and thyroid biopsy have 
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no role in the diagnose of this syndrome. There is no typical histological 
finding in thyroid biopsies. 
 THYROID PROFILE IN LOW T3 SYNDROME 
 
                                              Thyroid hormone estimation is the only test to                 
diagnose low T3 syndrome. The most common44 hormone pattern in sick 
euthyroid syndrome is a decrease in total T3 and free unbound T3 levels 
with normal levels of T4 and TSH. Reverse T3 levels are increased. 
 
                                              As the severity of the sick euthyroid syndrome 
increases, both serum T3 and T4 levels drop45  and gradually normalize as 
the patient recovers. TSH is affected in variable degrees, but, in the 
overwhelming majority of patients, TSH is in normal range. In severe, 
critical illness, some patients have reduced T4 levels.  
 
PATHOPHYSIOLOGY OF LOW T3 SYNDROME. 
 
           The following mechanisms are implicated in the pathogenesis of low 
T3 syndrome. 
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1. Impaired Peripheral deiodination of T4 to T3 secondary to 
decreased activity of type I deiodinase enzyme, which deiodinates 
T4 to T3. Normally 20% of T3 production comes from thyroidal 
secretion and 80% from peripheral deiodination of T4. Though 
production of T3 by thyroid gland is normal, peripheral production of 
T3 is decreased. Production of rT3 is unchanged, while its clearance 
is diminished leading to raised rT3 levels. 
 
2. Increased levels of Cytokines interleukin (IL)-1, IL-6, tumor necrosis 
factor (TNF)-alpha and interferon-beta decrease the activity of type I 
deiodinase and the binding capacity of T3 nuclear receptors. 
 
3. Presence of binding inhibitor in the serum and in body tissues that 
might inhibit uptake of thyroid hormones by cells or prevent binding 
to nuclear T3 receptors, thus inhibiting the action of the 
hormone.This inhibitor is associated ith the nonesterified fatty acid 
(NEFA) fraction in the serum. 
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4. Serum factors, such as bilirubin, NEFA, furanoic acid, hippuric acid, 
and indoxyl sulphate, present in various non thyroidal illness, have 
been shown to inhibit transport of thyroid hormones. 
 
5. Diminished T4 has been proposed to be due to low T4 binding 
globulin caused by protease cleavage at inflammatory sites in acute 
inflammatory conditions. Another   hypothesis for the cause of 
disproportionately low serum T4 concentrations in patients with low 
T3 syndrome is the presence of abnormal serum binding due to 
desialation of T4 binding globulin. 
 
6. Decreased nocturnal TSH surge ,blunting of TSH response to 
exogenous TRH and Decreased TRH gene expression46. 
MORTALITY/MORBIDITY IN LOW T3 SYNDROME 
 
                                     Mortality and morbidity depend on the severity and, 
possibly the duration of the underlying non-thyroid illness. The magnitude 
of the thyroid function test result abnormalities depend on the severity, 
rather than the type of illness. 
 24
LOW T3 SYNDROME AND CHRONIC HEART FAILURE 
                                               
                                     The cardiovascular system is one of the most 
important systems on which the thyroid hormones act.  Animal studies 
show that Cardiac myocyte gene expression and cardiac contractility are 
reduced in low T3 syndrome and improve significantly with T3 treatment24. 
The LV content of the SERCA2 mRNA is decreased significantly in the low-
T3  syndrome47. It is not known whether low-T3 syndrome is the cause or 
the effect of chronic heart failure48.However majority considered Low T3 
syndrome as an adaptive factor in minimizing the catabolic phenomena of 
heart failure. 
  
                                     Studies indicate that there is a poor relation 
between measures of cardiac performance and the symptoms of heart 
failure. Patients with very low ejection fraction may be asymptomatic, 
where as patients with preserved ejection fraction may develop severe 
symptoms. This discordance has necessitated research into the role of 
non-cardiac factors in determining clinical outcomes of heart failure. The 
existence of these non-cardiac factors may explain why similar 
pharmacological measures may not produce the same degree of response 
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in all patients. Thyroid hormone due to its fundamental role in 
cardiovascular homeostasis has been a major area of research in this 
context. Low T3 syndrome occurs early in chronic heart failure than in 
other chronic illnesses49. 
 
                                   The landmark study by Iervasi et al concluded that 
low T3 concentrations are a strong, independent predictive marker of poor 
prognosis in heart disease. Studies indicate the prevalence of low T3 
syndrome in heart failure between 18 % and 20 %.   Recently pingitore et 
al50 have shown that alterations in thyroid profile occur in asymptomatic 
and mildly symptomatic patients with LV dysfunction. 
 
                                   Opasich C et al51 in a large representative population 
of moderate to severe heart failure found that sick euthyroid patients have 
higher NYHA class, weight loss and low insulin levels. Serum 
norepinephrine levels and atrial natriuretic peptide levels were significantly 
higher in these patients.  
 
                                     Decreased FT3 levels and FT3/FT4 ratios correlate 
with reduced ejection fraction and increased chamber 
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dimension52..Shimoyama et al, demonstrated lower FT3 values in heart 
failure patients with ventricular tachycardia 53. A low free T3 index/reverse 
T3 ratio was associated with higher right atrial, pulmonary artery and 
pulmonary capillary wedge pressures and lower ejection fraction, cardiac 
index, serum sodium, albumin and total lymphocyte count54. It is not known 
whether sick euthyroid syndrome contributes to the development of heart 
failure or is only an attendant syndrome. 
 
LOW T3 SYNDROME THERAPEUTIC ASPECTS 
 
                                Limited numbers of studies have determined the 
effects of thyroid hormone supplementation in low T3 syndrome. In 23 
patients with advanced heart failure Hamilton et al found a single 
intravenous dose of 58 µg of triiodothyronine resulted in an increase in 
cardiac output and a decrease in systemic vascular resistance two hours 
after administration, without any evidence of myocardial ischemia, rhythm 
disturbances, or other untoward effects. High dose of triiodothyronine 
decreased systemic vascular resistance and increased cardiac output 
within hours after coronary artery bypass grafting55. 
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                              Moruzzi et al56, in a placebo controlled study of 20 
patients with chronic heart failure found that treatment with 0.1 mg of 
thyroxine daily for 12 weeks improved exercise performance, increased the 
cardiac index, and decreased systemic vascular resistance.  
 
                            Psirropoulos, D et al have found exercise training, 
through a wide variety of mechanisms, can normalise free triiodothyronine 
levels reverses sick euthyroid syndrome in heart failure57. 
 
                             3,5 doiodothyropropionic acid (DITPA ) is a thyroid 
hormone analog with relative selectivity for a form of the thyroid hormone 
receptor in the liver. DITPA improves systolic as well as diastolic function58 
and is presently under trials. 
 
                              Whether thyroid hormones should be used in all 
patients with low T3 syndrome remains controversial due to lack of large 
scale controlled trials. Safety and hemodynamic benefits of longer 
infusions, combined infusion with inotropic agents, oral triiodothyronine 
replacement therapy, and new triiodothyronine analogs have to be studied 
in future. 
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MATERIALS AND METHODS 
 
STUDY DESIGN 
  
 
                        Prospective study 
 
SETTING 
      All patients were prospectively enrolled from the 
Cardiology and Internal medicine department of Government 
General Hospital, chennai.3. 
 
SAMPLE 
                        145 patients with clinical evidence of heart failure 
were enrolled in this study. All patients had documented evidence 
of prior myocardial infarction and were on heart failure treatment for 
at least one month. Informed consent was obtained from all 
patients. 
 
INCLUSION CRITERIA 
1. Duration of heart failure for a minimum period of one month 
2. Left ventricle ejection fraction less than 45% 
3. Left ventricle end diastolic diameter more than 56 mm 
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EXCLUSION CRITERIA 
1. History or clinical or laboratory evidence of hypothyroidism 
2. History or clinical or laboratory evidence of hyperthyroidism 
3. Subclinical hypothyroidism and Subclinical hyperthyroidism 
4. Amiodarone therapy 
5. History of revascularisation procedures 
6. Clinical evidence of Sepsis  
7. Evidence of renal failure 
8. Any other severe systemic illness  
 
PROCEDURE 
  A questionnaire prepared noted the duration, 
symptoms and treatment of heart failure. Questions were asked in 
relation to chest pain, dyspnoea, syncope, cough, smoking and 
medications. All previous clinical records of the patients were 
analyzed in detail. Based on the degree of effort needed to elicit 
symptoms patients were assigned to NYHA (New York Heart 
Association) class I to IV.                       
                        A detailed physical examination was conducted to 
assess patients volume status (rales, edema, jugular venous 
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distension), weight, height, body mass index and orthostatic blood 
pressure changes.  
                        Complete blood count, blood glucose (fasting and 2 
hour post prandial), Fasting serum lipid profile, blood urea, serum 
creatinine and serum electrolytes were   measured in all patients. 
                         Two-dimensional echocardiography was done in 
the cardiology department of Government General Hospital all 
patients. All patients had an ejection fraction of less than 45 
percent and left ventricular end diastolic diameter greater  
than 56 mm. 
                         Thyroid hormone measurements TSH, total T3, 
total T4, free T3, free T4 were made in all patients in the same 
fasting morning sample. All the above data were obtained between 
two to five days of enrollment in the study. 
 
INSTRUMENTS 
 
1. ELECTROCARDIOGRAM:  
                                     All patients had 12 lead ECG, which was 
reviewed for evidence of atrial enlargement, ventricular 
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hypertrophy, evidence of antecedent myocardial infarction and 
conduction blocks 
2.CHEST X RAY: 
                             Chest x ray posteroanterior view was done in all 
patients to note pulmonary congestion, pleural effusion and to 
estimate cardio thoracic ratio. 
 
3. ECHOCARDIOGRAPHY: 
                                 M-mode echocardiography was used to 
assess left ventricle dimensions. Left ventricle internal dimension in 
end systole (LVESD) and end diastole (LVEDD) are measured at 
the level of mitral valve leaflet tips in parasternal long axis view. 
Measurements are taken from the endocardium of the left surface 
of the interventricular septum to the endocardium of the left 
ventricle posterior wall. In adults the normal range of LVEDD is 3.5 
to 5.6 centimeter. The normal range of LVESD is 2 to 4 
centimeter59. 
                                  2-D echo imaging in apical 4 chamber, 
parasternal long axis and parasternal short axis views were used to 
assess ventricular and valvular movement.  Ejection fraction was 
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estimated using Simpson’s method60. In this method multiple short 
axis views are taken along the LV long axis. Endocardial border is 
traced accurately and left ventricle cavity is divided into 20 slices of 
known thickness and diameter (D). Left ventricle end diastole and 
Left ventricle end systole volumes are estimated. 
Area of each slice=22/7 (D/2)2 
Volume of each slice = area X thickness. 
LV volume= volume of each slice X number of slices (20) 
              
            (Left ventricle end diastole volume - Left ventricle end                          
systole volume) X 100                          
 EF  =     
                                     Left ventricle end diastole volume  
 
 
 
LABORATORY METHODS                              
                                  Fasting plasma glucose was measured using 
glucose oxidase and pyruvate oxidase methods from overnight 
fasting sample and results were read by autoanalyser.2 hr 
postprandial glucose was measured 2 hrs after routine morning 
breakfast. 
                                 From patients height and weight body mass 
index (BMI) was calculated using the formula weight in kilograms 
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divided by square of height in meters. Serum cholesterol 
(enzymatic oxidase-peroxidase method), 
 Serum HDL (polyethylene glycol-CHOD-PAP method) 
Triglycerides (enzymatic calorimetric method) were measured 
using Erba XL 300 autoanalyser. Serum LDL was calculated using 
Friedewald’s formula61. 
     LDL-C = Total cholesterol-TGL/5 If TC less than 400 mg/dl.                               
                                       TSH, Total T3, Free T3, Total T4 and Free 
T4 were measured by chemiluminescent immuno assay (CLIA) 
method. The normal values of our laboratory were 
TSH: 0.35 to 4 mIu/L, Total T3: 80 to 200 ng/dl, 
Free T3: 2.3-4.2 pg/ml, Total T4: 4.5-12 microgram/dl, and 
Free T4 7.5 to 18 pg/ml. 
   DEFINITIONS: 
 1.Newyork Heart Association classification of heart failure62 
     Class I  No limitation: ordinary physical exercise                                           
                  does not cause undue fatigue, dyspnoea, or  
                  palpitations 
     Class II Slight limitation of physical activity: comfortable 
                   at rest but ordinary activity results in fatigue,  
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                   palpitation or dyspnoea                            
     Class III Marked limitation of physical activity: comfortable   
                   at rest but less than ordinary activity results in  
                   symptoms.                
     Class IV Unable to carry out any physical activity without  
                    discomfort: symptoms of heart failure are present 
                    even at rest with increased discomfort with any   
                    physical activity                
2.DYSLIPIDEMIA63 
 Any one of  
o Serum total cholesterol >/= 240 mg/dl 
o Serum HDL </= 40 mg/dl 
o Serum triglycerides >/= 200 mg/dl 
o Serum LDL >/= 160 mg/dl (ATP III guidelines)              
3.DIABETES MELLITUS64 
1. Plasma glucose of 126mg/dl or greater after overnight fasting 
2. Post prandial Plasma glucose of 200 mg/dl or greater 
3. Symptoms of DM with random glucose 200 mg/dl or greater 
4.SYSTEMIC HYPERTENSION 
                          Based on JNC 765 classification systolic BP of  
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140 mm Hg and above and diastolic BP of 90 mm Hg and above 
was defined as systemic hypertension.  
5.OBESITY  
                 Obesity is defined as body mass index more than 30 
kg/m2. 
FOLLOW UP 
                       Based on exclusion criteria 44 patients were 
excluded during initial evaluation. Follow up of 101 patients began 
when thyroid hormone levels were measured. Data were obtained 
during the scheduled monthly visits. 24 patients were lost during 
follow up period. 
                        25 patients died during the follow up period of 24 
months. Of the 25 patients, 15 patients died due to progressive 
heart failure, arrythmia, cardiac arrest or myocardial infarction.3 
patients had sudden death outside hospital. The cause of death in 
the other 7 patients could not be ascertained as some did not seek 
medical attention or hospital records during the time of death could 
not be obtained. 51 patients survived the 24-month period.25 
patients were lost during the follow up period. At the end of the 
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follow up period characteristics of the all-cause mortality of the died 
group and the survived group were compared and analysed. 
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STATISTICAL ANALYSIS 
 
                       Statistical analysis was carried out for the 76 
subjects (51 alive, 25 died). Age, sex, BMI, diabetes, 
hypertension, dyslipidemia, obesity, smoking, left ventricle end 
diastolic diameter, NYHA class, Ejection fraction, TSH, Total T3, 
Free T3, Total T4 and Free T4 were analysed.Results were 
expressed as Mean and Standard Deviation(SD). The 
significance of difference in means between two groups was 
calculated using student t test and the significance of difference 
in proportions using chi-square statistic. Statistical significance 
was taken when p<0.05.All variables with significant associations 
were entered in Cox proportional Hazard Model for multivariate 
analysis with 95% confidence intervals. Pearsons correlation 
was used to analyse correlation between variables that were 
found to be significant in multivariate analysis. All statistical 
analyses were performed using SPSS (statistical package for 
social sciences) software for windows. 
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                                    RESULTS 
 
 
Table 1 
 
Prevalence of low T3 levels 
 
 
                        
Total T3 N=76 
Percent with 
low T3 
   
T3< 80 24  
   
  18.24 
   
T3>/=80 52  
   
 
 
                                 Total T3 values of all the 76 patients were 
computed.24 of the 76 patients had Total T3 less than the lower 
limit of 80 ng/dl. The prevalence of low T3 is found to be 
18.24%. 
 
                                 Comparison of continuous variables age, 
BMI, NYHA class, EF, LVEDD and thyroid profile values was 
done with student t test. The mean age of patients in died group 
was 65.96 and 58.23 in the survived group. 
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Table 2 
 
Comparison of Age, BMI and NYHA class 
 
 
variable Group Number Mean SD P value 
     
Student 
t test 
      
 Died 25 65.96 4.18  
Age     0.001 
     Significant 
 Alive 51 58.23 6.07  
      
 Died 25 26.87 2.86  
BMI     0.43 
     NS 
 Alive 51 27.44 3.04  
      
 Died 25 3.32 0.8  
NYHA      
Class     0.02 
 Alive 51 2.8 0.98 Significant 
      
         NS- Not Significant 
 
                              P value less than 0.05 is considered 
statistically significant. Values are rounded up to two decimals. 
SD denotes standard deviation. 
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                                         There is significant difference in age 
and NYHA class between the two groups. The mean age was 
higher in the died group and these patients were in worse 
NYHA class.  
Table 3 
Analysis of Echocardiography parameters 
  
                                           Compared to patients who are alive, 
left ventricular end diastolic diameter was higher in those who 
died. The mean ejection fraction in died and alive groups were 
28.36 and 34.88 respectively. Persons who died had a 
significantly lower ejection fraction than those alive.                     
When the mean ejection fraction was compared between 
Variable Group N Mean SD P value 
     Student t test
 Died 25 28.36 6.75  
Ejection      
Fraction     0.001 
     Significant 
 Alive 51 34.88 5.45  
      
 Died 25 64.04 5.26  
      
LVEDD     0.001 
 Alive 51 60.84 3.49 Significant 
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patients with low total T3(T3<80 ng/dl) and normal T3, patients 
with low T3 had a mean ejection fraction of 29.2 and those with 
normal T3 levels had a mean ejection fraction of 34.78. This 
indicates mean ejection fraction is lower in patients with low 
total T3 levels. 
Table 4 
Analysis of TSH, Total T3, Free T3 levels 
  
  
Group       N 
   
MEAN      SD 
Student t 
test 
  Died 25 2.81 0.83   
            
TSH         P=0.51 
          NS  
  Alive 51 2.68 0.86   
            
            
  Died 25 75.09 25.64   
            
Total T3         P=0.001 
          Significant  
  Alive 51 130.23 33.39   
            
            
  Died 25 2.04 0.85   
            
FreeT3         P=0.001 
          Significant  
  Alive 51 3.35 0.67   
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                                   In alive group 9.8% had low total T3 
levels (< 80 ng/dl) as against 80% in those who died. The mean 
total T3 and free T3 levels were significantly less in died 
patients. 
Table 5 
Analysis of Total T4, Free T4 levels 
  
  
Group       N 
   
MEAN      SD 
Student 
t test 
            
  Died 25 7.21 1.52   
            
Total T4         P=0.07 
          NS  
  Alive 51 7.97 1.83   
            
            
  Died 25 13.76 2.67   
            
Free T4         P=0.26 
  Alive   51 14.47 2.53  NS  
       
           NS- Not Significant 
                                 
                               Mean total T4 was less in those who died. 
There was no statistical significance between the two groups in 
total T4 and Free T4 levels.  
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                                 Dichotomized variables sex, hypertension, 
obesity, diabetes, dyslipidemia, smoking were analysed using 
chi-square test. 
Table 6 
Sex characteristics 
 
 
      
Variable Alive Died Test value
    N % N % Chi-square 
            Test  
  Male 32 62.7 22 88   
             
             
Sex          χ2=4.57 
           P=0.03 
           Significant  
  Female 19 37.3 3 12   
             
              
 
 
                         22 (28.94%) of the 76 analysed were females. 
Males accounted for 88% of those who died. There exists a 
statistically significant difference in mortality between male and 
female sex. 
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Table 7 
Analysis of BMI, Diabetes, Hypertension 
Variable  Alive Dead Test value 
    N % N % Chi-square test 
              
  <25 16 31.4 6 24   
              
BMI           χ2=0.44 
            P=0.51 
  >/=25 35 68.6 19 76 NS 
              
  NO 32 62.7 15 60   
              
DM           χ2=0.05 
            P=0.81 
  YES 19 32.3 10 40 NS 
              
  NO 26 51 15 60   
              
SHT           χ2=0.55 
            P=0.45 
 YES 25 49 10 40 NS 
              
NS- Not Significant 
                         
                             Presence of diabetes, systemic hypertension 
or BMI>/= 25 were not significantly different in those who died, 
compared to those who survived. 
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Table 8 
Analysis of Dyslipidemia, Obesity,B-blocker use, smoking 
 
Variable   Alive Dead Test value
    N % N % Chi-square test
 NO 27 53 16 64   
             
Dyslipidemia      χ2=0.84 
      P=0.36 
 YES 24 47 9 36 NS 
             
 NO 33 64.7 20 80   
       
Obesity      χ2=1.86 
      P=0.17 
 YES 18 35.3 5 20 NS  
       
 NO 20 39.2 11 44   
             
B-blocker      χ2=0.16 
Use      P=0.69 
 YES 31 60 14 56  NS 
             
 NO 25 49 12 48   
             
Smoking      χ2=0.01 
      P=0.091 
 YES 26 51 13 52 NS 
       
NS- Not Significant 
                             Dyslipidemia, Obesity, B-blocker use, 
smoking did not influence mortality significantly. 
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              From the above analysis Age, sex, NYHA class, 
ejection fraction, LVEDD, Total T3and Free T3 were 
significantly altered in died patients. To assess the influence of 
these parameters on mortality multivariate analysis was done. 
Because total T3 and free T3 are highly correlated we did not 
include free T3 in the same proportional hazard model. 
 
Table 9 
Cox proportional Hazard Model for Heart failure mortality 
 
 
Variable Significance
Odds 
ratio 95% CI 
      Lower Upper 
Age .001 45.453 5.420 381.145 
Sex .045 .260 .070 .968 
LVEDD .636 .784 .286 2.148 
EF .041 2.455 1.025 6.967 
Total T3 .001 19.05 4.65 111.1 
NYHA .118 1.564 .892 2.741 
 
 
                                     Age, sex, EF (ejection fraction) and total 
T3 were significant. Association between these variables was 
evaluated by Pearson product moment correlation test. 
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Table 10 
Association of total T3 with EF, Age, Sex 
Variable   EF Age Sex 
      
 Pearson Correlation. r 0.405 -0.346 0.054 
 (2 tailed)    
      
Total T3 Significance <0.001 0.002 0.641 
   Significant Significant NS 
 N  76 76 76 
      
               NS- Not Significant 
               Correlation is significant at 0.01 level (2-tailed). 
                                
                     The results show a significant correlation of total 
T3 with ejection fraction, indicating patients who have low 
ejection fraction have low total T3 levels. Total T3 levels did not 
correlate with sex. There is significant correlation between 
advancing age and lower total T3 levels. 
                    Using a cutoff total T3 level of 80 ng/dl (the lower 
limit of normal) two subgroups were identified and Kaplan-Meier 
survival analysis was compiled. Survival at 24 months in low 
total T3 group was found to be less than the group with total T3 
80 ng/dl and above.                                     
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                                              Table 11 
                               Analysis of follow up period 
 Survival N Mean Std. Deviation Student t-test
 
Months 
 
Alive 51 24.00 .000 
  
Died 25 12.80 5.315 
 
P=0.001 
Significant 
                                 
                             There was statistical significance in the follow 
up period. The median survival was 14 months (95% 
confidence interval (CI): 9-19 mths). 
                                               Table 12 
                         Analysis of median survival in months 
Group Median survival 95% CI 
    
Alive 24  22-24 
    
    
Dead 14  9-19 
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Kaplan-Meier 24-month survival curves for all cause 
mortality in two sub groups identified according to total T3 
cutoff value of 80 ng/dl. 
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DISCUSSION 
                             In this study of Indian population involving 76 
patients, we evaluated the prevalence of low T3 syndrome in 
chronic heart failure. We found the prevalence of low T3 syndrome 
to be 18.24%. This is with in the range as described in other 
studies.  Studies by Opasich et al51 and Kozdag et al52 observed a 
prevalence of 18% and 21% respectively. The landmark study by 
Iervasi et al66 involving 573 patients with heart disease found a 
prevalence of 30%. In India Zargar et al67 studied sick euthyroid 
syndrome in chronic non-thyroidal illness and found a prevalence of 
20.60%  
  STUDY  POPULATION COUNTRY PREVALENCE OF 
      LOW T3 SYNDROME
       
       
Opasich et al Chronic Heart Failure Italy  18% 
       
       
Iervasi et al Patients with heart Italy  30% 
  disease    
       
Zargar et al Chronic non thyroid India  20.60% 
               illness    
       
This study Chronic Heart Failure India  18.24% 
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                        Patients with Low total T3 values (T3<80ng/dl) had 
lower mean ejection fraction (29.2) than those with total T3 values 
of 80 ng/dl and above (34.78). This observation is consistent with 
the earlier study by Kozdag et al, who found that patients with Low 
T3 syndrome have lower ejection fraction. 
   
                        In univariate analysis, We find advancing age, male 
sex, higher NYHA ciass, high left ventricular end diastolic diameter, 
lower ejection fraction, low total T3 and free T3 levels are 
associated with increased mortality. The mean total T3 levels and 
free T3 levels were lower in patients who died. Similar results were 
reported by Pingitore et al in their study on risk stratification in 
chronic heart failure, who found age, male sex, NYHA ciass, left 
ventricular end diastolic diameter, ejection fraction, total T3 and 
free T3 levels and obesity as significant univariate mortality 
predictors. However In our study, there was no significant 
association between obesity and mortality. 
  
                       In a multivariate model with total T3, we find that 
Age, male sex, ejection fraction and total T3 are the significant 
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predictors of increased mortality. In comparison, the study by 
Alessandro et al reported male sex, ejection fraction and total T3 as 
the multivariate predictors of increased mortality.  We find 
advancing age is also a significant multivariate predictor of 
increased mortality, in contrast to the study by Pingitore et al68. 
 
                        We found a significant correlation of low total T3 
levels with ejection fraction, indicating that patients who have low 
ejection fraction have low total T3 levels. Similarly Kozdag G et al 
found a significant correlation between low T3 values and reduced 
ejection fraction. This is in contrast to the study by Pingitore et al 
who did not find any correlation between low total T3 and ejection 
fraction. 
 
                        We also found a significant correlation of low total 
T3 levels with advancing age. However, Pingitore et al reported no 
correlation between age and low T3 levels in a study. 
 
                        From our multi variate analysis, we find that age, 
ejection fraction and total T3 levels are associated with increased 
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mortality. Also, there is significant correlation of total T3 levels with 
age and ejection fraction. Hence, total T3 is an important predictor 
of mortality, but not the only predictor. Similarly, Opasich et al in a 
study on 199 chronic heart failure patients observed that Low T3 
syndrome was not an independent negative prognostic factor but 
has a definite role when used with other parameters. 
 
                      There is considerable diversity of opinions as to 
Whether T3 levels alone can be used to estimate mortality or not. 
Studies by Pingitore et al and Iervasi et al found T3 levels are 
independent predictors of mortality in patients with chronic heart 
failure. But Opasich et al and in this study we find that Total T3 is 
significant but not the only parameter that estimates mortality. 
  
                        In conclusion Total T3 levels are an important 
parameter in survival estimation of patients with chronic heart 
failure and should be used along with other conventional 
parameters like age and ejection fraction.  
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                             Our study has the following limitations. We have 
studied patients with chronic heart failure following myocardial 
infarction. We have not included patients with chronic heart failure 
due to other causes. We could not estimate reverse T3 levels due 
to practical reasons. In our study we measured thyroid profile at the 
base line and assessed its relationship to subsequent clinical 
events. However if thyroid hormone levels are measured 
frequently, its association with outcomes can be identified 
accurately. 
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CONCLUSIONS 
 
 
 
• Thyroid function tests are significantly altered in patients 
with chronic heart failure 
• The prevalence of low T3 syndrome in chronic heart failure 
is 18.24% 
• Patients with low total T3 levels have lower ejection fraction 
• Advancing age correlates with reduced total T3 levels. 
• Total T3, ejection fraction and age are the most important 
predictors of mortality in this patient population. 
• Total T3 levels can be used as an adjunct to other 
parameters for risk stratification and survival estimation in 
chronic heart failure. 
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SCOPE FOR FUTURE STUDIES 
 
 
 
• Large-scale studies are needed to evaluation of the role of 
thyroid hormone supplementation in chronic heart failure. If 
beneficial results could be demonstrated this could be a cost 
effective measure to reduce the high mortality associated 
with this condition. 
• Frequent estimating thyroid hormone levels at various stages 
of heart failure can help in better understanding of the role of 
thyroid hormone in cardiovascular homeostasis. 
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PROFORMA 
 
Study on prevalence and significance of low T3 syndrome in 
chronic heart failure 
 
 
NAME:                                                             
 
AGE: 
 
SEX:  
 
OCCUPATION: 
 
HEIGHT (METERS): 
 
WEIGHT (Kg): 
 
BODY MASS INDEX (Kg/m2): 
 
HISTORY OF PRESENTING ILLNESS: 
 
1.DYSPNOEA                                                   YES/NO 
2.ORTHOPNEA                      YES/NO 
3.PND                                                                 YES/NO 
4. FATIGUE                                                       YES/NO 
4.ANGINA                                                         YES/NO 
5.SYNCOPE                                                       YES/NO 
6.CYANOSIS                                                     YES/NO 
7.PALPITATIONS                                             YES/NO 
8.COUGH                                                           YES/NO 
9.EXPECTORATION                                        YES/NO 
10.PEDAL EDEMA                                           YES/NO 
 
PAST HISTORY: 
 
   1.DIABETES                                                    YES/NO (HOW MANY YEARS) 
    2.HYPERTENSION                                         YES/NO (HOW MANY YEARS) 
    3.MYOCARDIAL INFARCTION                    DATE 
            THROMBOLYSIS/PCI 
                                                      DURATION OF HOSPITALIZATION 
    4.ARRYTHMIAS                                             YES/NO 
    5.AMIODARONE                                            YES/NO (HOW MANY YEARS) 
    6.BETA-BLOCKER                                         YES/NO (HOW MANY YEARS) 
    7.ACE INHIBITOR                                          YES/NO (HOW MANY YEARS) 
    8.SMOKING                                                    YES/NO (HOW MANY YEARS) 
    9.THYROID ILLNESS                                    YES/NO (HOW MANY YEARS) 
    10.ALCOHOL          YES/NO (HOW MANY YEARS) 
    11.ANY OTHER DRUGS/REMEDIES 
 
 
 
GENERAL EXAMINATION: 
 
• CONSCIOUSNESS 
• PALLOR 
• TEMPERATURE 
• CYANOSIS 
• PEDAL EDEMA 
• ICTERUS 
• THYROID SWELLING 
 
PULSE RATE:                                              BLOOD 
PRESSURE:(STANDING&SUPINE) 
 
JVP:       TEMPERATURE : 
 
SYSTEMIC EXAMINATION: 
 
      CARDIOVASCULAR SYSTEM: 
 
      MURMURS:                                                                 YES/NO 
      LVH:                                                                              YES/NO 
      RVH:                                                                              YES/NO 
      S3:              LV/RV                                                        YES/NO 
      NYHA CLASS (I-IV):                                         
 
     RESPIRATORY SYSTEM: 
 
     CREPITATIONS:                                                            YES/NO 
     PLEURAL EFFUSION:                                                  YES/NO 
 
     ABDOMEN 
 
     ASCITES:                                                                        YES/NO 
     HEPATOMEGALY:                                                       YES/NO 
 
    CENTRAL NERVOUS SYSTEM: 
 
INVESTIGATIONS: 
 
   1. COMPLETE BLOOD COUNT 
                   HEMOGLOBIN 
                   TOTAL COUNT 
                   DIFFERENTIAL COUNT 
                   ESR 
                   PLATELET COUNT 
 
     2. BLOOD UREA 
 
     3.BLOOD GLUCOSE FASTING                                             2hr POST PRANDIAL 
 
     4.SERUM CREATININE 
              
     5.SERUM ELECTROLYTES 
       
     6. FASTING SERUM 
                                     CHOLESTEROL 
                                     TRIGLYCERIDES 
                        LDL 
                                     VLDL 
 
    7.SERUM PROTEIN TOTAL 
                                        ALBUMIN 
                                        GLOBULIN 
  
    8.URINE ANALYSIS 
 
    9. CHEST X RAY       CTR               PLEURAL EFFUSION 
 
    10.ELECTROCARDIOGRAM 
       RATE 
          RHYTHM 
          P WAVE 
          P-R INTERVAL 
          QRS AXIS 
          QRS MORPHOLOGY 
          T WAVE 
          OTHERS 
 
    11.ECHOCARDIOGRAPHY 
         LEFT VENTRICLE END DIASTOLIC DIAMETER(LVEDD)                                    
         LEFT VENTRICLE END SYSTOLIC DIAMETER (LVESD) 
         EJECTION FRACTION (EF %) 
         LEFT ATRIAL ENLARGEMENT 
         MITRAL REGURGITATION 
         WALL MOTION ABNORMALITY 
         PULMONARY ARTERY PRESSURE 
         PERICARDIAL EFFUSION 
 
     12. THYROID PROFILE  
                                       TSH               
                                       TOTAL T3    
                                       FREE T3       
                                       TOTAL T4    
                                       FREE T4  
      
FOLLOW UP: 
 
VISIT NUMBER: 
COMPLAINTS: 
DATE OF DEATH: 
CAUSE OF DEATH: 
 
 
MASTER CHART 
 
 DIED AGE S BMI DM HT SM TC TG HDL LDL B-B EDD EF TSH
T 
T3 FT3 TT4 
F 
T4 NYHA
Follow 
up 
1 karruppan 66 1 23.2 0 0 1 260 211 36 217 1 58 30 3.2 58 1.7 6.2 11 4 11 
2 chinnaiah 68 1 27.9 0 1 1 145 150 44 115 0 66 34 2.2 107 3.4 7.9 15 3 15 
3 kuppan 72 1 26.4 1 1 1 246 264 50 189 1 65 25 3.8 59 1.6 6.5 13 4 18 
4 govindan 76 1 29 0 0 1 180 176 42 141 1 58 20 2.9 62 1.6 9.6 17 4 14 
5 selvan 62 1 30.4 1 1 0 221 268 40 214 0 59 16 3.5 52 1.6 6.1 12 2 6 
6 duraisamy 68 1 23.3 1 0 1 165 154 46 123 1 60 40 2.5 130 3.9 5.9 9.8 3 23 
7 chellappan 66 1 26.2 0 0 0 190 190 42 152 0 66 32 1.9 76 2.2 7.3 14 4 12 
8 kaliyaperumal 63 1 29.3 0 0 1 136 154 55 105 1 69 24 3.3 54 1.7 5.8 12 3 9 
9 rajamanikkam 68 1 30.8 1 1 1 179 169 48 145 1 75 22 3.6 53 1.4 7.6 16 4 7 
10 kabilan 64 1 27.5 1 1 1 298 210 24 256 0 58 34 3.3 130 3.9 9.5 17 3 16 
11 thomas 66 1 26 0 1 0 195 162 45 163 1 65 30 2 68 1.6 6.2 11 4 11 
12 ismail 63 1 25.4 0 0 1 187 153 42 156 1 67 32 3.5 51 1.1 5.9 13 2 13 
13 alla baksh 64 1 22 1 1 0 194 146 47 165 0 64 24 1.5 78 2.2 8.6 18 3 12 
14 karmegam 62 1 28.4 0 0 1 176 196 50 137 1 60 32 3 100 2.7 5.3 12 4 9 
15 stalin 62 1 31 1 0 1 178 198 42 138 1 61 30 3.8 52 1.4 7.9 15 3 17 
16 ravi 59 1 27.1 0 1 0 234 290 20 176 0 64 26 3.7 58 1.6 7.6 15 4 18 
17 issac 70 1 26.3 1 0 1 178 155 48 147 0 76 18 2.6 78 2.2 7.9 15 3 4 
18 chandran 63 1 22.6 0 0 0 169 189 43 131 1 58 30 3 61 1.5 6.9 15 3 9 
19 mayilsamy 69 1 26.7 0 1 1 290 198 28 250 1 57 34 3.1 138 3.9 6.9 15 1 15 
20 ranganathan 67 1 23.5 0 0 0 149 150 49 119 0 62 40 1.1 70 1.5 8.4 16 3 16 
21 selvam 69 1 26 1 0 0 187 166 44 154 1 63 32 0.9 73 1.9 5.3 11 4 9 
22 rajaram 57 1 27 0 0 0 197 154 50 166 0 64 28 2.8 75 2.1 7.2 14 3 14 
23 kanaga 66 2 32 0 1 0 190 310 35 128 1 66 18 3.8 63 1.1 11 18 4 2 
24 dhanam 69 2 26 0 0 0 190 156 55 159 0 74 30 2.5 74 1.9 5.8 11 4 20 
25 mariyammal 70 2 23.8 1 0 0 186 180 48 150 0 65 36 2.6 66 1.7 9.1 17 3 15 
 ALIVE AGE S BMI DM HT SM TC TG HDL LDL B-B EDD EF TSH TT3 FT3 TT4 F T4 NYHA followup
1 muthulaksmi 59 2 31 0 1 0 265 220 35 210 0 57 34 3.6 110 3.3 6.5 11.9 4 24 
2 muniammal 60 2 33 0 1 0 186 154 58 155 1 59 40 3.5 126 3.6 5.4 9.5 2 24 
3 kanagammal 57 2 26 1 0 0 241 266 40 188 1 60 38 3.3 109 3.2 7.6 15.2 3 24 
4 rajathi 64 2 26 0 1 0 310 298 26 250 1 56 30 2.4 117 3.5 9.6 16.2 4 24 
5 sundari 71 2 28 0 0 0 234 290 20 176 1 59 32 1.9 149 4 6.1 13.4 4 24 
6 papathi 64 2 28 0 1 0 198 189 54 160 1 66 40 3.3 171 3.7 12 17.6 2 24 
7 lakshmi 53 2 31 0 0 0 296 180 40 260 0 67 36 3.6 181 3.9 7.3 14.3 1 24 
8 seethalakshmi 59 2 23 1 1 0 192 198 48 152 1 58 38 3.6 51 1.6 5.4 9.6 4 24 
9 rajammal 56 2 31 0 0 0 260 165 45 227 1 60 34 0.9 99 3.1 12 17.6 2 24 
10 shanthamani 65 2 31 1 0 0 250 150 40 220 1 68 36 2.6 98 2.8 11 16.9 4 24 
11 sorna 49 2 26 0 1 0 230 190 35 192 0 56 40 3.1 136 3.1 6.2 13.9 2 24 
12 jothi 51 2 25 0 1 0 190 150 41 160 1 58 35 2.4 70 2 6.6 12.5 2 24 
13 kannagi 50 2 23 0 0 0 154 146 48 125 1 59 30 3.2 143 3.4 6.6 14.7 4 24 
14 gethalakshmi 63 2 32 1 1 0 190 256 45 139 0 58 32 0.8 129 3.7 12 15.5 2 24 
15 rose 66 2 29 1 0 0 187 146 42 158 1 60 36 1.3 145 3.8 7.9 15.7 3 24 
16 anushammal 54 2 31 0 0 0 290 198 30 250 1 61 38 0.8 98 3.3 7.6 14.9 2 24 
17 kuppammal 59 2 27 1 1 0 181 175 42 144 0 58 36 3.2 128 3.7 5.8 7.8 3 24 
18 natarajan 56 1 32 0 0 1 210 220 45 166 0 57 44 2.2 66 1.8 11 17.2 1 24 
19 kaman 55 1 31 1 1 1 243 197 40 104 1 60 40 3.8 87 2.7 10 15.2 4 24 
20 rajan 58 1 25 0 1 1 174 187 50 137 0 66 42 2.9 158 3.9 8.4 14.6 2 24 
21 subramani 60 1 24 1 0 1 260 168 36 226 1 63 32 3.5 182 4 5.3 7.6 3 24 
22 chellan 62 1 23 0 1 0 190 169 30 156 0 61 36 2.4 130 2.9 9.1 14.7 2 24 
23 kasi 59 1 25 1 0 1 186 198 43 146 1 61 35 1.9 155 3.7 11 17.5 4 24 
24 kannan 52 1 31 0 1 0 210 159 44 178 0 57 30 3.4 163 4.2 5.8 12.6 2 24 
25 balasubramani 51 1 24 0 0 1 190 167 45 157 0 59 28 3.6 145 3.4 9.5 12.9 4 24 
 
 
1-yes 
2-no 
S = sex,1=male, 2= female 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 ALIVE AGE S BMI DM HT SM TC TG HDL LDL B-B EDD EF TSH
T 
T3
F 
T3 TT4 F T4 NYHA
follow 
up 
26 ajithdas 50 1 31 1 1 0 245 240 35 197 1 60 34 2.2 172 3.8 8.7 16.9 2 24 
27 arumugam 60 1 25 1 0 1 300 198 25 260 1 66 42 2 149 3.7 6.8 12.2 4 24 
28 pandurangan 55 1 25 0 0 1 176 164 54 143 1 60 36 3.1 170 4 7.4 15.9 2 24 
28 sheikh 54 1 24 0 1 1 230 178 40 194 0 58 36 2.3 138 4.1 6.9 14.6 1 24 
30 rangasamy 58 1 27 0 1 1 224 159 45 192 1 61 42 3.3 130 3.9 9.5 17 2 24 
31 sundaram 60 1 26 1 0 1 187 104 40 166 1 61 30 2.8 75 1.9 8.7 16.6 3 24 
32 etti 58 1 26 0 1 0 197 137 50 170 0 60 44 3.6 180 3.4 5.9 8.4 2 24 
33 rajan 55 1 30 0 1 1 166 178 36 131 1 57 35 3.9 150 3.8 6.1 14.7 3 24 
34 raghavan 61 1 31 0 0 1 290 298 24 231 1 59 28 2.9 162 3.5 6.6 15.5 4 24 
35 sundaram 53 1 31 1 1 1 220 146 30 191 0 58 20 2.4 144 3.7 7.3 14.9 2 24 
36 gopal 52 1 23 0 1 0 190 158 30 159 1 66 40 1.9 177 3.9 5.8 12.2 4 24 
37 vembu 55 1 24 0 0 1 279 145 35 250 1 65 32 2.5 94 2.8 7.6 16.1 2 24 
38 mookandi 58 1 25 0 1 0 145 132 48 119 0 69 34 3.6 173 3.8 11 17.2 3 24 
39 muniazhagan 57 1 28 1 0 1 240 154 46 209 1 64 36 2.2 164 4 6.2 11.2 2 24 
40 avinasi 69 1 26 0 1 1 190 177 42 155 0 59 20 2.6 139 3.6 5.8 13.3 4 24 
41 thangaraj 70 1 31 0 0 1 176 167 30 143 0 63 30 0.9 124 3.7 8.7 15.9 2 24 
42 duraisamy 72 1 28 1 1 0 156 123 50 131 1 68 40 2 147 3.8 8.1 15.4 3 24 
43 umapathy 59 1 25 0 0 1 310 220 35 266 0 60 28 3.5 120 2.4 7.9 14.9 3 24 
44 govindan 76 1 30 0 1 1 190 198 52 159 1 59 34 1.5 126 3.1 7.7 13.8 2 24 
45 natarajan 55 1 24 1 0 1 230 180 40 194 0 60 32 1.9 142 3.8 7.9 15.2 2 24 
46 partheeban 54 1 27 1 0 1 197 178 42 161 1 57 44 3.8 139 3.9 6.9 15.2 4 24 
47 manickam 57 1 26 0 0 1 188 167 44 155 1 66 38 3.7 129 2.8 8.6 16.6 2 24 
48 veeraraghavan 57 1 31 1 1 1 254 165 45 221 0 65 30 2.6 111 3.6 8.5 17.4 4 24 
49 shanthanam 60 1 28 0 0 0 154 109 53 132 1 61 28 1.9 69 1.9 8.2 15.9 4 24 
50 kannan 52 1 31 1 0 1 229 190 30 191 0 60 32 2.8 94 3 9.1 14.8 4 24 
51 veerapan 50 1 26 0 0 1 163 178 46 127 1 57 42 3.5 85 2.5 11 16.5 3 24 
 
 
 
1-yes 
2-no 
S = sex, 1=male, 2= female 
 
 
